JP2022521502A5 - - Google Patents

Info

Publication number
JP2022521502A5
JP2022521502A5 JP2021547879A JP2021547879A JP2022521502A5 JP 2022521502 A5 JP2022521502 A5 JP 2022521502A5 JP 2021547879 A JP2021547879 A JP 2021547879A JP 2021547879 A JP2021547879 A JP 2021547879A JP 2022521502 A5 JP2022521502 A5 JP 2022521502A5
Authority
JP
Japan
Prior art keywords
antisense oligonucleotide
bond
sequence
administration
oligonucleotide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021547879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/055071 external-priority patent/WO2020174023A1/en
Publication of JP2022521502A publication Critical patent/JP2022521502A/ja
Publication of JP2022521502A5 publication Critical patent/JP2022521502A5/ja
Ceased legal-status Critical Current

Links

JP2021547879A 2019-02-26 2020-02-26 脆弱ｘ精神遅滞タンパク質干渉オリゴヌクレオチドおよびその使用方法 Ceased JP2022521502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810697P 2019-02-26 2019-02-26
US62/810,697 2019-02-26
PCT/EP2020/055071 WO2020174023A1 (en) 2019-02-26 2020-02-26 Fragile x mental retardation protein interfering oligonucleotides and methods of using same

Publications (2)

Publication Number Publication Date
JP2022521502A JP2022521502A (ja) 2022-04-08
JP2022521502A5 true JP2022521502A5 (https=) 2023-03-03

Family

ID=69723929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547879A Ceased JP2022521502A (ja) 2019-02-26 2020-02-26 脆弱ｘ精神遅滞タンパク質干渉オリゴヌクレオチドおよびその使用方法

Country Status (12)

Country Link
US (1) US20220145303A1 (https=)
EP (1) EP3931324A1 (https=)
JP (1) JP2022521502A (https=)
KR (1) KR20210132678A (https=)
CN (1) CN113748207A (https=)
AU (1) AU2020228134A1 (https=)
BR (1) BR112021016907A2 (https=)
CA (1) CA3130854A1 (https=)
EA (1) EA202192330A1 (https=)
MX (1) MX2021010255A (https=)
SG (1) SG11202109112WA (https=)
WO (1) WO2020174023A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025501755A (ja) * 2021-12-23 2025-01-23 ユニバーシティー オブ マサチューセッツ 脆弱ｘ関連障害に対する治療的処置
CN121109315A (zh) * 2025-08-28 2025-12-12 同济大学 脆性x智力障碍1号基因在治疗或缓解骨关节炎中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
US8679757B2 (en) * 2009-03-24 2014-03-25 Asuragen, Inc. PCR methods for characterizing the 5′ untranslated region of the FMR1 and FMR2 genes
EP2488665B1 (en) * 2009-10-16 2017-12-13 National University of Singapore Screening method for trinucleotide repeat sequences
US20120231015A1 (en) * 2009-11-06 2012-09-13 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
AU2011273360A1 (en) * 2010-07-02 2013-02-07 Vib Vzw The role of Fragile X mental retardation gene and protein in cancer metastasis
CN103981253A (zh) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒
WO2017049192A1 (en) * 2015-09-17 2017-03-23 University Of Massachusetts Compositions and methods for modulating fmr1 expression
EP3368089B1 (en) * 2015-10-26 2025-11-05 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
WO2019154884A1 (en) * 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
CN108531576A (zh) * 2018-04-12 2018-09-14 北京信诺佰世医学检验所有限公司 检测脆性x染色体综合征的试剂盒和系统

Similar Documents

Publication Publication Date Title
AU698442B2 (en) Modified oligonucleotides, their preparation and their use
JP2022106727A5 (https=)
CA2459347C (en) Locked nucleic acid (lna) compositions and uses thereof
US5837835A (en) Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US6140496A (en) Precursors for deoxyribonucleotides containing non-standard nucleosides
US20020013287A1 (en) Polymeric compounds useful as prodrugs
AU643972B2 (en) Oligoribonucloside and oligodeoxyribonucleoside boranophosphates
CN1863813B (zh) 作为治疗剂的三环核苷或核苷酸
JP7798836B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
CN113286803A (zh) S-抗原转运抑制寡核苷酸聚合物和方法
WO2006121820A1 (en) Phosphoramidate prodrugs for treatment of viral infection
HUT76094A (en) Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
AU2017326372B2 (en) Modified oligonucleotides and methods of use
JP7558963B2 (ja) 修飾されたマイクロｒｎａ及びがんの処置におけるその使用
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
EP3682007A2 (en) Galnac derivatives
JP2023515218A (ja) Ｐｄ－ｌ１を標的とするための方法及び組成物
IL185569A (en) Cyclic acid and analogues of nucleotide nucleotides and oligonucleotides
JP2022521502A5 (https=)
WO2018048937A1 (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
JP2007533742A5 (ja) 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
WO2015158913A1 (en) Novel antiviral and antitumoral compounds
EP2970355A1 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
JP2007510405A5 (https=)